AM 831

Drug Profile

AM 831

Alternative Names: AM831; PCAP programme

Latest Information Update: 19 Jul 2012

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ACADIA Pharmaceuticals
  • Class Antipsychotics; Small molecules
  • Mechanism of Action Dopamine D2 receptor antagonists; Muscarinic M1 receptor agonists; Serotonin 2A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Schizophrenia

Most Recent Events

  • 13 Jul 2012 Discontinued - Phase-I for Schizophrenia in USA (PO)
  • 09 Nov 2011 Phase-I clinical trials in Schizophrenia in USA (PO)
  • 07 Nov 2011 US FDA approves IND application for AM 831 in Schizophrenia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top